Kerry Wentworth - 21 Jun 2021 Form 4 Insider Report for Flexion Therapeutics Inc

Role
Chief Regulatory Officer
Signature
/s/ Mark S. Levine, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
21 Jun 2021
Net transactions value
+$4,193
Form type
4
Filing time
28 Jun 2021, 18:09:25 UTC
Previous filing
25 May 2022
Next filing
20 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FLXN Common Stock Award $4,193 +539 +0.37% $7.78 144,306 21 Jun 2021 Direct F1
holding FLXN Common Stock 6,000 21 Jun 2021 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is being filed voluntarily to report the acquisition of 539 shares by the Reporting Person on June 21, 2021, pursuant to the Issuer's Employee Stock Purchase Plan.